Skip to main content

Zhiweixincai (Xi'an) Technology

MaterialsXi'an, ChinaFounded 2021· One of 961 Materials companies tracked by AMPulse

A technology-based enterprise specializing in 3D bioprinting equipment and high-performance metal materials such as titanium alloy welding wire for additive manufacturing.

CEO / Founder
李逸昕
Team Size
1-10
Stage
Active
Total Funding
$4.9M
Latest Round
Pre-Series A
Key Investors
CASStar (中科创星), Shaanxi Financial Holding Group, Xi'an High-tech Gold Control

Technology & Products

Key Products

MewOne series 3D bioprinters (specialized for biological materials and cell printing); High-performance titanium alloy welding wire (e.g., TC4/Gr5); Specialized wire for Plasma Atomization (PA) metal powder production; Metal filaments for Fused Filament Fabrication (FFF) 3D printing; Metal powders for additive manufacturing (including martensitic steel and various alloys); Ceramic and gypsum-based 3D printing materials

Technological Advantage

Defensible hardware advantage through IP-protected equipment including the 'Series of Ring Tangent Line Equipment (QG1600)' and the 'AFE45 3D Printing Filament Extrusion Line.' These systems allow for the verified production of specialized wire for Plasma Atomization (PA) and metal FFF filaments, providing a manufacturing capability that is more defensible than standard printer assembly.

Differentiation

Value Proposition

Zhiweixincai (Xi'an) Technology Co., Ltd is a technology-based enterprise specializing in the dual fields of 3D bioprinting and high-performance metal additive manufacturing materials. The company focuses on providing high-precision bioprinting equipment and specialized metal consumables, such as titanium alloy welding wire, to bridge the gap between advanced material science and biomedical applications.

How They Differentiate

Differentiates from niche bioprinting or metal powder competitors by offering a cross-disciplinary material range (biological cells, titanium alloys, martensitic steel, and ceramics) and the specific industrial machinery required to produce AM consumables. While most bioprinting firms focus solely on hydrogels, Zhiweixincai integrates high-performance metal wire production for aerospace and industrial applications.

Market & Competition

Target Customers

Research institutions, universities, medical device manufacturers, aerospace component suppliers, and metal powder production facilities.

Industry Verticals

Biomedical & Healthcare; Aerospace & Defense; Industrial Manufacturing; Academic Research & Education

Competitors

Xi'an Bright Laser Technologies; Changzhou Vnici Digital Technology Co., Ltd

Growth & Milestones

Growth Metrics

location: Xi'an, Shaanxi Province, China. industry_focus: 3D Bioprinting, Metal Additive Manufacturing, Filament Extrusion Equipment. exhibition_presence: Active participant in major industrial AM trade shows (TCT Asia)

Major Milestones

Exhibited at TCT Asia 2024 (Booth 7K126), showcasing the MewOne 3D printer and specialized metal/wire processing equipment.; Developed the QG1600 series of Ring Tangent Line Equipment for specialized material cutting and preparation in additive manufacturing.; Launched the MewOne 3D PRINTER, targeting the 3D bioprinting and professional additive manufacturing markets.; Exhibited at TCT Asia 2026 (Booth 7K126), showcasing titanium alloy wire products and metal AM materials.

https://www.zhiweixincai.com

Why this company matters

Zhiweixincai (Xi'an) Technology Co., Ltd occupies a niche at the intersection of 3D bioprinting and metal additive manufacturing. Rather than focusing on a single material class, the company develops both biological-material printers and the industrial machinery needed to produce metal consumables such as titanium alloy welding wire and metal filaments for FFF. This dual capability is unusual among early-stage Chinese AM firms, which typically specialize in either bioprinting hydrogels or metal powder production.

The company's core technology stack includes proprietary hardware: the QG1600 series Ring Tangent Line Equipment for specialized material cutting and preparation, and the AFE45 3D Printing Filament Extrusion Line for producing metal and ceramic filaments. On the bioprinting side, the MewOne series targets research institutions and medical device manufacturers needing high-precision cell and biomaterial printing. For metal AM, it supplies TC4/Gr5 titanium alloy wire for directed energy deposition and wire feedstock for plasma atomization powder production.

Target customers span academic research labs, aerospace component suppliers, and metal powder producers. The company has exhibited at TCT Asia in 2024 and 2026, signaling active engagement with the industrial AM community. With $4.9M in disclosed funding from Casstar, Shaanxi Financial Holding Group, and Xi'an High-tech Gold Control, and a team of 1-10 employees, it remains an early-stage player building credibility through trade-show presence and a vertically integrated product line.

The strategic moat lies in the combination of material processing hardware and consumable production, which is more defensible than assembling standard printers. However, the company faces established competitors like Xi'an Bright Laser Technologies in metal AM and Changzhou Vnici in bioprinting. Its cross-disciplinary range—from biological cells to titanium alloys and ceramics—creates differentiation but also risks spreading limited resources across two demanding markets. The open question is whether the dual focus will yield sufficient traction in either segment to achieve scale.